LP

LB Pharmaceuticals Inc Common Stock

LBRX·NASDAQ

$27.95

+3.4%
HealthcareBiotechnology

Clinical‑stage biopharmaceutical company developing novel therapies for neuropsychiatric diseases (e.g. schizophrenia, bipolar depression). Lead candidate is LB‑102, a methylated derivative of amisulpride.

At a Glance

Live Snapshot
Market Cap$801.51M
EPS-1.0000
P/E Ratio-27.95
Earnings Date06/25/2026

lbrx

Sales/Maturities of Investments

Last Annual Value

5.00M

3-Year CAGR

244%

5-Year CAGR

110%

10-Year CAGR

45%

LP

LB Pharmaceuticals Inc Common Stock Competitors Analysis of Sales/Maturities of Investments

LBRX · NASDAQ
CompanySales/Maturities of Investments
CAGR 3Y
CAGR 5Y
CAGR 10Y
5.00M
-5.9%N/AN/A 
120.00M
-0.1%N/AN/A
ANNX logo
Annexon, Inc.
NASDAQ:ANNX
402.40M
31.0%23.7%N/A
139.01M
-18.8%-17.4%N/A
HUMA logo
Humacyte, Inc.
NASDAQ:HUMA
0.00
N/AN/AN/A
398.81M
104.4%N/AN/A
374.68M
-17.3%-9.5%N/A
386.48M
-4.5%13.4%N/A
56.70M
-19.0%N/AN/A
380.76M
7.2%6.9%21.0%
KRRO logo
Korro Bio, Inc.
NASDAQ:KRRO
70.70M
55.0%N/AN/A
LP

LB Pharmaceuticals Inc Common Stock Fair Value Envelope

LBRX · NASDAQ

Our analysis suggests that LBRX has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $27.95, this represents a potential HIDDEN relative to our calculated worth for LB Pharmaceuticals Inc Common Stock.

Intrinsic Value
Current Price: $27.95